These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14571193)

  • 1. Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz.
    Bosch RJ; Downey GF; Katzenstein DA; Hellmann N; Bacheler L; Albrecht MA;
    AIDS; 2003 Nov; 17(16):2395-6. PubMed ID: 14571193
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Zhou T; Xie L
    Yao Xue Xue Bao; 2004 Aug; 39(8):666-72. PubMed ID: 15563074
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA; Bosch RJ; Hellmann N; Wang N; Bacheler L; Albrecht MA;
    AIDS; 2003 Apr; 17(6):821-30. PubMed ID: 12660529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain.
    Cocuzza AJ; Chidester DR; Cordova BC; Jeffrey S; Parsons RL; Bacheler LT; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 2001 May; 11(9):1177-9. PubMed ID: 11354371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
    Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
    J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations.
    Eshleman SH; Jones D; Galovich J; Paxinos EE; Petropoulos CJ; Jackson JB; Parkin N
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):289-93. PubMed ID: 16545016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
    Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
    Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
    [No Abstract]   [Full Text] [Related]  

  • 9. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
    Brenner B; Turner D; Oliveira M; Moisi D; Detorio M; Carobene M; Marlink RG; Schapiro J; Roger M; Wainberg MA
    AIDS; 2003 Jan; 17(1):F1-5. PubMed ID: 12478089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequencing antiretroviral drugs.
    Soriano V
    AIDS; 2001 Mar; 15(5):547-51. PubMed ID: 11316990
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.
    Whitcomb JM; Huang W; Limoli K; Paxinos E; Wrin T; Skowron G; Deeks SG; Bates M; Hellmann NS; Petropoulos CJ
    AIDS; 2002 Oct; 16(15):F41-7. PubMed ID: 12370521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV-1 polymorphism and development of resistance mutations against non-nucleoside reverse transcriptase inhibitor, efavirenz].
    Gatanaga H
    Jpn J Antibiot; 2005 Feb; 58(1):99-104. PubMed ID: 15847224
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.
    Crespan E; Locatelli GA; Cancio R; Hübscher U; Spadari S; Maga G
    Antimicrob Agents Chemother; 2005 Jan; 49(1):342-9. PubMed ID: 15616314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA).
    Patel M; McHugh RJ; Cordova BC; Klabe RM; Erickson-Viitanen S; Trainor GL; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3221-4. PubMed ID: 10576692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors.
    Clark SA; Shulman NS; Bosch RJ; Mellors JW
    AIDS; 2006 Apr; 20(7):981-4. PubMed ID: 16603849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
    Shulman N; Zolopa AR; Passaro D; Shafer RW; Huang W; Katzenstein D; Israelski DM; Hellmann N; Petropoulos C; Whitcomb J
    AIDS; 2001 Jun; 15(9):1125-32. PubMed ID: 11416714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
    Corbett JW; Ko SS; Rodgers JD; Gearhart LA; Magnus NA; Bacheler LT; Diamond S; Jeffrey S; Klabe RM; Cordova BC; Garber S; Logue K; Trainor GL; Anderson PS; Erickson-Viitanen SK
    J Med Chem; 2000 May; 43(10):2019-30. PubMed ID: 10821714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
    Figueiredo A; Moore KL; Mak J; Sluis-Cremer N; de Bethune MP; Tachedjian G
    PLoS Pathog; 2006 Nov; 2(11):e119. PubMed ID: 17096588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.